Ishwaria Subbiah was named executive director of cancer care equity and professional wellness at Sarah Cannon Research Institute. In this role, Subbiah will focus on reducing cancer outcomes disparities and diversifying clinical trial participation within SCRI’s combined research network of over 1,300 physicians at over 250 locations in 24 states across the U.S.
Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
